An October 2026 randomized pilot trial published in Obesity Science & Practice evaluated digital wellness support and medically tailored meals versus usual care among 39 U.S. adults after discontinuing GLP-1 medication.
Researchers Compare Digital Wellness Support and Tailored Meals After GLP-1 Discontinuation
Published October 7, 2026, in Obesity Science & Practice, a randomized pilot trial examined strategies to reduce weight regain following GLP-1 medication discontinuation. Hollis-Hansen et al. (2026) reported lower estimated weight regain over four months among participants receiving digital wellness support or medically tailored meals compared with usual care. For Med Spas and medical weight-loss clinics, the findings provide data on behavioral and nutritional support during the post-treatment period.
Four-Month Results Show Differences in Weight Gain Across Study Groups
Hollis-Hansen et al. (2026) conducted a fully remote randomized pilot trial from March 2024 to August 2025 involving 39 adults who had lost more than 10% of their body weight while receiving GLP-1 therapy and had discontinued treatment within the preceding 30 days. Participants were recruited through obesity medicine clinics in Dallas and El Paso, Texas, and an online research recruitment platform.
Participants were randomly assigned to three groups:
- Usual care (14 participants): Continued weight-management care according to their healthcare provider’s usual practices, without an additional study intervention.
- Digital wellness application (12 participants): Received access to the Noom app, which provided behavioral education, food tracking, physical activity monitoring, and weight-management tools.
- Medically tailored meals (13 participants): Received 10 dietitian-developed, prepared meals weekly for four months.
Participants recorded their weight using Bluetooth-enabled scales approximately monthly, with 34 completing a final weigh-in.
The study reported the following model-estimated changes in body weight over four months:
- Usual care: 10.75% weight gain
- Digital wellness application: 3.60% weight gain
- Medically tailored meals: 3.58% weight gain
Compared with usual care, estimated weight gain was 7.16 percentage points lower in the digital wellness group and 7.17 percentage points lower in the medically tailored meals group. In their discussion, Hollis-Hansen et al. (2026) noted that structured behavioral and nutritional support may help limit early weight regain following GLP-1 discontinuation. The authors also identified the small sample size, short follow-up period, and variations in usual care as study limitations.
Source Publication
According to Hollis-Hansen et al. (2026), the randomized pilot trial evaluated digital wellness support and medically tailored meals to support weight maintenance after discontinuing GLP-1 therapy. “Preventing Weight Regain After Glucagon-Like Peptide-1 Therapy Discontinuation: A Pilot Randomized Controlled Trial” was published on October 7, 2026, in Obesity Science & Practice and is available under DOI 10.1002/osp4.70194.
DISCOVER YOUR MED SPA’S GROWTH POTENTIAL
How much time and revenue could you unlock by outsourcing your GFEs?
Use our GFE Calculator to find out in under 5 minutes. It’s quick, easy, and tailored to your Med Spa.
Post-GLP-1 Research and Broader Weight-Management Developments
In addition to weight regain, Hollis-Hansen et al. (2026) evaluated treatment adherence and satisfaction as primary outcomes, along with diet quality and perceived health. The study found no statistically significant differences among the three groups on these measures. Participants assigned to the wellness application reported using it an average of 2.8 days weekly, while those receiving medically tailored meals consumed an average of 8.08 meals per week.
Hollis-Hansen et al. (2026) identified several factors contributing to GLP-1 medication discontinuation, including:
- Medication costs
- Insurance coverage limitations
- Medication side effects
- Patient preferences
The authors discussed how behavioral and nutritional support may help limit early weight regain following GLP-1 discontinuation. Broader U.S. research has also documented prescription weight-management services across healthcare and wellness settings. A September 2026 Whelth Research analysis of 14,748 U.S. Med Spa websites found that 40.1% listed medical weight loss among their services. Separately, a March 2026 Inspire360 report on GLP-1 program models identified 17 fitness operators offering weight-loss programs through clinical partnerships, referrals, and in-club services.
Hollis-Hansen et al. (2026) found that behavioral and nutritional support may help limit early weight regain following GLP-1 discontinuation.
At the federal level, the FDA published 17 revised draft product-specific guidances on July 28, 2026, covering peptide drugs, including semaglutide, tirzepatide, and liraglutide. The guidance provides recommendations for generic drug development and product-specific testing.
For Med Spa and medical weight-loss operators, further research on post-GLP-1 weight maintenance may clarify long-term patient outcomes. Hollis-Hansen et al. (2026) called for larger, longer-term trials to identify which patients may benefit from behavioral and nutritional support after treatment discontinuation.
Practical Implications for Med Spa and Medical Weight-Loss Operators
- Assess the role of digital tracking tools in patient engagement and weight monitoring.
- Distinguish weight-regain findings from treatment adherence, satisfaction, and diet-quality outcomes.
- Educate patients on behavioral support and structured nutrition as potential weight-maintenance strategies, as applicable.
- Recognize medication costs, insurance limitations, and patient preferences as reported factors in GLP-1 discontinuation.
- Monitor future research on long-term weight maintenance and patient outcomes following GLP-1 discontinuation.
What to Watch Next
Hollis-Hansen et al. (2026) identified the need for studies with at least one year of follow-up to assess whether differences in weight regain persist over time. The authors also recommended further research on intervention adherence, costs, and outcomes of behavioral and nutritional support, both separately and in combination, following GLP-1 discontinuation.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Female bare feet approaches scale” by P Stock, via Vecteezy, available under the Vecteezy Free License.
